Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease bronchitis
Phenotype C0600260|obstructive pulmonary disease
Sentences 11
PubMedID- 26528246 Impaired mucociliary clearance (mcc) is a hallmark of acquired chronic airway diseases like chronic bronchitis associated with chronic obstructive pulmonary disease (copd) and asthma.
PubMedID- 23152680 Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly medicare population.
PubMedID- 22723325 Context: the phosphodiesterase 4 inhibitor roflumilast is a first-in-class antiinflammatory treatment for severe chronic obstructive pulmonary disease (copd) associated with chronic bronchitis and a history of frequent exacerbations.
PubMedID- 22284994 Background: roflumilast is a newly approved phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease (copd) associated with chronic bronchitis and a history of exacerbations.
PubMedID- 23392624 Objective: to estimate the cost-effectiveness of adding a selective phosphodiesterase-4 inhibitor, roflumilast, to a long-acting bronchodilator therapy (laba) for the treatment of patients with severe-to-very severe chronic obstructive pulmonary disease (copd) associated with chronic bronchitis with a history of frequent exacerbations from the uk payer perspective.
PubMedID- 23865594 In the post-hib vaccine era, non-typeable h. influenzae (nthi) continue to cause infections of the respiratory tree including otitis media (om), conjunctivitis, sinusitis, pneumonia, and bronchitis especially in patients with chronic obstructive pulmonary disease (copd); as well as playing a role in early colonization of the lower respiratory tracts of children with cystic fibrosis [23,24].
PubMedID- 20723142 Chronic obstructive pulmonary disease in the absence of chronic bronchitis in china.
PubMedID- 24152603 Objective: roflumilast is the first phosphodiesterase 4 (pde4) inhibitor approved for the treatment of chronic obstructive pulmonary disease (copd) associated with chronic bronchitis and history of exacerbations.
PubMedID- 25568518 Next by the frequency is acute bronchitis with 10%, chronic obstructive pulmonary disease (copd) with 7%, while chronic bronchitis was present in only 4%.
PubMedID- 23605250 Nontypeable haemophilus influenzae (nthi) is an opportunistic pathogen and a common cause of otitis media in children, chronic bronchitis, and pneumonia in patients with chronic obstructive pulmonary disease.
PubMedID- 23768858 Background and objective: roflumilast is a recently marketed drug, indicated for maintenance treatment of severe chronic obstructive pulmonary disease associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.

Page: 1